From small beginnings: to build an anti-eugenic future
By Benedict Ipgrave, Miroslava Chavez-Garcia, Marcy Darnovsky, Subhadra Das, Charlene Galarneau, Rosemarie Garland-Thomson, Nora Ellen Groce, Tony Platt, Milton Reynolds, Marius Turda, Robert A Wilson,
The Lancet
| 05. 21. 2022
September, 1921 was unusually hot and New York was sweltering. For the many immigrants who crowded the city's tenements and pavements, one of the few places for relief from the incessant heat was the American Museum of Natural History. That summer the museum presented a new exhibition with rows of human skulls, snapshots of patients in psychiatric institutions, and the preserved brain of a serial killer. It was all terribly macabre. The immigrants among the museum's visitors who read the leaflet distributed at the entrance soon discovered that this exhibition was all about them. It included charts showing how migration eroded societies, statistics from IQ tests of arrivals at Ellis Island, and posters spouting anti-migrant rhetoric. All conveyed the same message: “your tired, your poor, your huddled masses yearning to breathe free” were not welcome here.
Meanwhile, just upstairs the Second International Eugenics Congress was in full swing. The ramifications of this conference would be felt across the world. Leading eugenicists at the conference argued that the science of eugenics would enable the betterment of the human “race” by selective...
Related Articles
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Sophie Alexander and Ike Swetlitz, Bloomberg | 06.25.2025
A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley’s ultra-rich turn their attention to one of the most controversial technologies in medicine.
Bootstrap Bio...